Precision BioSciences, Inc. Common Stock (DTIL) Stock Price

DTILStock

$7.78+54.98%52W

Market Cap$214.74M

P/E19.04x

PEG Ratio—

Div yield—

Beta1.31

DTIL Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)82.57%

Price vs S&P 500 (4W)8.66%

VGM Score66.51

P/E Ratio (Annual)19.04x

Book Value / Share (Quarterly)$1.71

P/TBV (Annual)1.10x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)10.93%

Cash Flow / Share (Quarterly)$-1.98

Price vs S&P 500 (YTD)74.20%

Net Profit Margin (TTM)-96.73%

EPS (TTM)$-2.80

10-Day Avg Trading Volume0.31M

EPS Excl Extra (TTM)$-2.80

Revenue Growth (5Y)7.13%

EPS (Annual)$-3.56

ROI (Annual)-39.88%

Net Profit Margin (5Y Avg)-144.03%

Cash / Share (Quarterly)$3.31

Revenue Growth QoQ (YoY)37272.41%

P/E Normalized (Annual)19.04x

ROA (Last FY)-29.61%

Revenue Growth TTM (YoY)3472.96%

EBITD / Share (TTM)$-1.73

ROE (5Y Avg)-116.05%

Operating Margin (TTM)-86.85%

Cash Flow / Share (Annual)$-2.76

P/B Ratio4.42x

P/B Ratio (Quarterly)4.48x

Net Income / Employee (Annual)$-672,400

EV / Revenue (TTM)3.03x

Net Interest Coverage (TTM)-8.08x

ROA (TTM)-40.74%

EV / EBITDA (TTM)19.13x

EPS Incl Extra (Annual)$-3.56

Current Ratio (Annual)13.32x

Quick Ratio (Quarterly)12.26x

3-Month Avg Trading Volume0.37M

52-Week Price Return54.98%

Revenue / Employee (TTM)$662,600

Tangible BV / Share (Quarterly)$1.67

P/S Ratio (Annual)5.85x

Asset Turnover (Annual)0.22x

52-Week High$9.62

Operating Margin (5Y Avg)-120.10%

EPS Excl Extra (Annual)$-3.56

CapEx CAGR (5Y)-32.60%

Tangible BV CAGR (5Y)16.17%

26-Week Price Return94.50%

Quick Ratio (Annual)12.97x

13-Week Price Return12.43%

Total Debt / Equity (Annual)0.24x

Current Ratio (Quarterly)12.82x

Enterprise Value$136.73M

Revenue / Share Growth (5Y)-28.21%

Asset Turnover (TTM)0.36x

Book Value / Share Growth (5Y)-31.45%

Revenue / Employee (Annual)$503,900

Pretax Margin (Annual)-136.03%

Cash / Share (Annual)$4.80

3-Month Return Std Dev66.22%

Net Income / Employee (TTM)$-775,500

ROE (Last FY)-49.57%

Net Interest Coverage (Annual)-1.31x

EPS Basic Excl Extra (Annual)$-3.56

Receivables Turnover (TTM)22.51x

Total Debt / Equity (Quarterly)0.49x

EPS Incl Extra (TTM)$-2.80

Receivables Turnover (Annual)40.36x

ROI (TTM)-65.94%

P/S Ratio (TTM)4.45x

Pretax Margin (5Y Avg)-105.97%

Revenue / Share (Annual)$2.67

Tangible BV / Share (Annual)$3.78

Price vs S&P 500 (52W)36.42%

Year-to-Date Return87.02%

5-Day Price Return-7.93%

EPS Normalized (Annual)$-3.56

ROA (5Y Avg)-24.82%

Net Profit Margin (Annual)-133.45%

Month-to-Date Return11.30%

Cash Flow / Share (TTM)$-0.62

EBITD / Share (Annual)$-3.95

Operating Margin (Annual)-152.30%

LT Debt / Equity (Annual)0.24x

ROI (5Y Avg)-69.42%

LT Debt / Equity (Quarterly)0.49x

EPS Basic Excl Extra (TTM)$-2.80

P/TBV (Quarterly)4.59x

P/B Ratio (Annual)1.09x

Pretax Margin (TTM)-98.70%

Book Value / Share (Annual)$3.83

Price vs S&P 500 (13W)10.47%

Beta1.31x

P/FCF (Annual)2.22x

Revenue / Share (TTM)$1.74

ROE (TTM)-91.60%

52-Week Low$3.53

vGradeC

gGradeA

mGradeB

vgmGradeB

DTIL Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	-$0.69	-$1.26	-81.73%(-$0.57)
Q1 2026	May 5, 2026	-$0.81	-$0.75	+7.41%(+$0.06)
Q4 2025	Mar 12, 2026	-$0.64	$1.01	+256.36%(+$1.65)
Q3 2025	Nov 3, 2025	-$2.21	-$1.84	+16.74%(+$0.37)
Q2 2025	Aug 7, 2025	-$2.21	-$2.13	+3.40%(+$0.08)

DTIL Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.30

4.36

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
DTILPrecision BioSciences, Inc. Common Stock	C	A	B	$7.78
AMGNAmgen Inc	C	C	B	$432.42
GILDGilead Sciences Inc	C	B	B	$145.68
ARGXargenx SE American Depositary Shares	D	A	B	$1023.21
MRNAModerna, Inc. Common Stock	D	C	A	$137.99
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$207.88
BIIBBiogen Inc. Common Stock	C	D	B	$218.50
BNTXBioNTech SE American Depositary Share	C	C	C	$102.08
NBIXNeurocrine Biosciences Inc	C	B	C	$154.06
EXELExelixis Inc	C	B	B	$54.45
HALOHalozyme Therapeutics, Inc.	C	B	B	$105.35
TECHBio-Techne Corp.	D	C	B	$72.35
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$351.46
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.97
RGENRepligen Corp	D	C	B	$176.27
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$118.15
PCVXVaxcyte, Inc. Common Stock	—	—	B	$59.84
QGENQIAGEN N.V.	C	C	B	$43.11
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$141.38
IBRXImmunityBio, Inc. Common Stock	F	A	B	$8.05
IMVTImmunovant, Inc. Common Stock	—	—	B	$41.20
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$57.80
CGONCG Oncology, Inc. Common stock	F	A	B	$74.34
CRSPCRISPR Therapeutics AG	D	B	C	$57.72
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	$18.77
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$25.19
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.00
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.01
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.76
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$29.32
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.82
KODKodiak Sciences Inc Common Stock	—	—	B	$37.72
MESOMesoblast Limited American Depositary Shares	D	B	B	$17.44
VCELVericel Corporation	D	B	B	$40.95
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$44.84
ADMAADMA Biologics, Inc.	C	C	C	$9.34
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$36.62
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$5.77
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.83
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	$123.41
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.34
ALVOAlvotech Ordinary Shares	C	D	C	$4.95
NVAXNovavax Inc	B	D	C	$9.26
MAZEMaze Therapeutics, Inc. Common Stock	—	—	C	$27.44
SLBTSL Science Holding Limited Ordinary Shares	—	—	C	$2.70
REPLReplimune Group, Inc.	—	—	A	$15.50
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.45
VORVor Biopharma Inc. Common Stock	—	—	B	$22.65
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$21.70
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	B	$13.82
SANASana Biotechnology, Inc. Common Stock	—	—	B	$3.93

About Precision BioSciences, Inc. Common Stock

Precision BioSciences develops genome editing therapeutics based on its proprietary ARCUS platform. The platform's compact size enables efficient delivery to a wider range of cells and tissues using both viral and non-viral methods, potentially providing competitive advantages. The company applies ARCUS to create product candidates for human disease treatment and agricultural applications.